Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes

Dermatologic Clinics

Volumn 30, Issue 1, 2012, Pages 113-124

  Tuong, William ^a   Cheng, Lily S ^a   Armstrong, April W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cause; Epidemiology; Melanoma; Prevention; Prognosis; Treatment

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; IPILIMUMAB; LYCOPENE; RESVERATROL; SELENIUM; SORAFENIB; SUNSCREEN; VASCULOTROPIN ANTIBODY;

ADJUVANT THERAPY; AGE; BODY DISTRIBUTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 9P; CLINICAL FEATURE; DRUG EFFICACY; EARLY DIAGNOSIS; FAMILY HISTORY; GENE LOCUS; GENE MUTATION; GINSENG; HUMAN; IMMUNOTHERAPY; LYMPH NODE; LYMPH NODE BIOPSY; LYMPHADENECTOMY; MELANOCYTE; MELANOMA; MOHS MICROGRAPHIC SURGERY; NEVUS; OVERALL SURVIVAL; PATHOGENESIS; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PUNCH BIOPSY; PUVA; RACE DIFFERENCE; RADIATION EXPOSURE; RADIOTHERAPY; REGIONAL METASTASIS; REVIEW; RISK FACTOR; SELF EXAMINATION; SEX DIFFERENCE; SKIN BIOPSY; SKIN PIGMENTATION; SOLAR RADIATION; SUN EXPOSURE; SUNBURN; SURGICAL TECHNIQUE; SURVIVAL RATE; TEA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; UNITED STATES; WIDE EXCISION; XERODERMA PIGMENTOSUM;

DERMATOLOGY; HUMANS; INCIDENCE; MELANOMA; OUTCOME ASSESSMENT (HEALTH CARE); SKIN NEOPLASMS; UNITED STATES;

EID: 82455216803     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.08.006     Document Type: Review

References (106)

1. Howe H.L., Wingo P.A., Thun M.J., et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001, 93(11):824-842.
2. Erickson C., Driscoll M.S. Melanoma epidemic: facts and controversies. Clin Dermatol 2010, 28(3):281-286.
3. Linos E., Swetter S.M., Cockburn M.G., et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129(7):1666-1674.
4. Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics review, 1975-2007. 2009. Available at: Accessed April 6, 2011. http://seer.cancer.gov/csr/1975_2007.
5. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
6. Jemal A., Murray T., Samuels A., et al. Cancer statistics, 2003. CA Cancer J Clin 2003, 53(1):5-26.
7. Fast Stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Available at: Accessed November 4, 2011. http://seer.cancer.gov/faststats.
8. Hausauer A.K., Swetter S.M., Cockburn M.G., et al. Increases in melanoma among adolescent girls and young women in California: trends by socioeconomic status and UV radiation exposure. Arch Dermatol 2011, 147(7):783-789.
9. Rigel D.S. Epidemiology of melanoma. Semin Cutan Med Surg 2010, 29(4):204-209.
10. Merrill R.M., Pace N.D., Elison A.N. Cutaneous malignant melanoma among white Hispanics and non-Hispanics in the United States. Ethn Dis 2010, 20(4):353-358.
11. Jemal A., Devesa S.S., Hartge P., et al. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001, 93(9):678-683.
12. Koh H.K., Norton L.A., Geller A.C., et al. Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program. J Am Acad Dermatol 1996, 34(6):971-978.
13. Robinson J.K., Rigel D.S., Amonette R.A. Trends in sun exposure knowledge, attitudes, and behaviors: 1986 to 1996. J Am Acad Dermatol 1997, 37(2 Pt 1):179-186.
14. Geller A.C., Annas G.D. Epidemiology of melanoma and nonmelanoma skin cancer. Semin Oncol Nurs 2003, 19(1):2-11.
15. Montagna W., Carlisle K. The architecture of black and white facial skin. J Am Acad Dermatol 1991, 24(6 Pt 1):929-937.
16. Pho L., Grossman D., Leachman S.A. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 2006, 18(2):173-179.
17. Uribe P., Wistuba I.I., Solar A., et al. Comparative analysis of loss of heterozygosity and microsatellite instability in adult and pediatric melanoma. Am J Dermatopathol 2005, 27(4):279-285.
18. Bandarchi B., Ma L., Navab R., et al. From melanocyte to metastatic malignant melanoma. Dermatol Res Pract 2010, 2010. pii: 583748.
19. Smalley K.S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010, 130(1):28-37.
20. Puzanov I., Burnett P., Flaherty K.T. Biological challenges of BRAF inhibitor therapy. Mol Oncol 2011, 5(2):116-123.
21. Cannon-Albright L.A., Goldgar D.E., Meyer L.J., et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992, 258(5085):1148-1152.
22. Kamb A., Shattuck-Eidens D., Eeles R., et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994, 8(1):23-26.
23. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat Genet 1994, 8(1):15-21.
24. Lin J., Hocker T.L., Singh M., et al. Genetics of melanoma predisposition. Br J Dermatol 2008, 159(2):286-291.
25. Quelle D.E., Zindy F., Ashmun R.A., et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83(6):993-1000.
26. Pollock P.M., Harper U.L., Hansen K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1):19-20.
27. Randerson-Moor J.A., Harland M., Williams S., et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001, 10(1):55-62.
28. Hewitt C., Lee Wu C., Evans G., et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002, 11(11):1273-1279.
29. Rizos H., Puig S., Badenas C., et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 2001, 20(39):5543-5547.
30. Bishop D.T., Demenais F., Goldstein A.M., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002, 94(12):894-903.
31. Begg C.B., Orlow I., Hummer A.J., et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005, 97(20):1507-1515.
32. El Ghissassi F., Baan R., Straif K., et al. A review of human carcinogens-part D: radiation. Lancet Oncol 2009, 10(8):751-752.
33. Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001, 63(1-3):8-18.
34. Berwick M., Halpern A. Melanoma epidemiology. Curr Opin Oncol 1997, 9(2):178-182.
35. Lee J.A., Strickland D. Malignant melanoma: social status and outdoor work. Br J Cancer 1980, 41(5):757-763.
36. Elwood J.M., Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997, 73(2):198-203.
37. Dennis L.K., Vanbeek M.J., Beane Freeman L.E., et al. Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis. Ann Epidemiol 2008, 18(8):614-627.
38. Pfahlberg A., Kolmel K.F., Gefeller O. Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation-induced melanoma. Br J Dermatol 2001, 144(3):471-475.
39. Levine J.A., Sorace M., Spencer J., et al. The indoor UV tanning industry: a review of skin cancer risk, health benefit claims, and regulation. J Am Acad Dermatol 2005, 53(6):1038-1044.
40. Choi K., Lazovich D., Southwell B., et al. Prevalence and characteristics of indoor tanning use among men and women in the United States. Arch Dermatol 2010, 146(12):1356-1361.
41. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007, 120(5):1116-1122.
42. Cho E., Rosner B.A., Feskanich D., et al. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005, 23(12):2669-2675.
43. Ford D., Bliss J.M., Swerdlow A.J., et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995, 62(4):377-381.
44. Hemminki K., Zhang H., Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003, 120(2):217-223.
45. Ferrone C.R., Ben Porat L., Panageas K.S., et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005, 294(13):1647-1654.
46. Green A.C., O'Rourke M.G. Cutaneous malignant melanoma in association with other skin cancers. J Natl Cancer Inst 1985, 74(5):977-980.
47. Marghoob A.A., Slade J., Salopek T.G., et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995, 75(Suppl 2):707-714.
48. Lindelof B., Sigurgeirsson B., Wallberg P., et al. Occurrence of other malignancies in 1973 patients with basal cell carcinoma. J Am Acad Dermatol 1991, 25(2 Pt 1):245-248.
49. MacKie R.M., Hauschild A., Eggermont A.M. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009, 20(Suppl 6):vi1-vi7.
50. Olsen C.M., Carroll H.J., Whiteman D.C. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010, 3(2):233-245.
51. Gandini S., Sera F., Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005, 41(14):2040-2059.
52. Lin J.Y., Fisher D.E. Melanocyte biology and skin pigmentation. Nature 2007, 445(7130):843-850.
53. Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum. GeneReviews [internet]. Seattle (WA): University of Washington, Seattle;2003. Available at: Accessed August 19, 2011. http://www.ncbi.nlm.nih.gov/books/NBK1397.
54. Stern R.S. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001, 44(5):755-761.
55. Friedman R.J., Rigel D.S., Kopf A.W. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985, 35(3):130-151.
56. Abbasi N.R., Shaw H.M., Rigel D.S., et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004, 292(22):2771-2776.
57. Rigel D.S., Russak J., Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010, 60(5):301-316.
58. Wang S.Q., Hashemi P. Noninvasive imaging technologies in the diagnosis of melanoma. Semin Cutan Med Surg 2010, 29(3):174-184.
59. Garbe C., Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009, 27(1):3-9.
60. Elwood J.M., Gallagher R.P. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int J Cancer 1998, 78(3):276-280.
61. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206.
62. Au A., Ariyan S. Melanoma of the head and neck. J Craniofac Surg 2011, 22(2):421-429.
63. Zager J.S., Hochwald S.N., Marzban S.S., et al. Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg 2011, 212(4):454-460.
64. Karimipour D.J., Schwartz J.L., Wang T.S., et al. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol 2005, 52(5):798-802.
65. Ng J.C., Swain S., Dowling J.P., et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol 2010, 146(3):234-239.
66. Duncan L.M. The classification of cutaneous melanoma. Hematol Oncol Clin North Am 2009, 23(3):501-513. ix.
67. Porras B.H., Cockerell C.J. Cutaneous malignant melanoma: classification and clinical diagnosis. Semin Cutan Med Surg 1997, 16(2):88-96.
68. Clark W.H., Elder D.E., Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986, 17(5):443-450.
69. Clark W.H., Mihm M.C. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969, 55(1):39-67.
70. Cohen L.M. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995, 33(6):923-936. [quiz: 937-40].
71. Markovic S.N., Erickson L.A., Rao R.D., et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007, 82(3):364-380.
72. Bradford P.T., Goldstein A.M., McMaster M.L., et al. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 2009, 145(4):427-434.
73. Coleman W.P., Loria P.R., Reed R.J., et al. Acral lentiginous melanoma. Arch Dermatol 1980, 116(7):773-776.
74. Scolyer R.A., Long G.V., Thompson J.F. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011, 5(2):124-136.
75. Buka R., Friedman K.A., Phelps R.G., et al. Childhood longitudinal melanonychia: case reports and review of the literature. Mt Sinai J Med 2001, 68(4-5):331-335.
76. Narayanan D.L., Saladi R.N., Fox J.L. Ultraviolet radiation and skin cancer. Int J Dermatol 2010, 49(9):978-986.
77. Bataille V., de Vries E. Melanoma-Part 1: epidemiology, risk factors, and prevention. BMJ 2008, 337:a2249.
78. Lin J.S., Eder M., Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 154(3):190-201.
79. Bordeaux J.S., Lu K.Q., Cooper K.D. Melanoma: prevention and early detection. Semin Oncol 2007, 34(6):460-466.
80. Gimotty P.A., Glanz K. Sunscreen and melanoma: what is the evidence?. J Clin Oncol 2011, 29(3):249-250.
81. Austoker J. Melanoma: prevention and early diagnosis. BMJ 1994, 308(6945):1682-1686.
82. Rager E.L., Bridgeford E.P., Ollila D.W. Cutaneous melanoma: update on prevention, screening, diagnosis, and treatment. Am Fam Physician 2005, 72(2):269-276.
83. Francis S.O., Mahlberg M.J., Johnson K.R., et al. Melanoma chemoprevention. J Am Acad Dermatol 2006, 55(5):849-861.
84. Jensen J.D., Wing G.J., Dellavalle R.P. Nutrition and melanoma prevention. Clin Dermatol 2010, 28(6):644-649.
85. Egan K.M. Vitamin D and melanoma. Ann Epidemiol 2009, 19(7):455-461.
86. Wolff T., Tai E., Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 150(3):194-198.
87. Hamidi R., Peng D., Cockburn M. Efficacy of skin self-examination for the early detection of melanoma. Int J Dermatol 2010, 49(2):126-134.
88. Sladden M.J., Balch C., Barzilai D.A., et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009, 4. CD004835.
89. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998, 14(4):272-275.
90. Cook J. Surgical margins for resection of primary cutaneous melanoma. Clin Dermatol 2004, 22(3):228-233.
91. Dawn M.E., Dawn A.G., Miller S.J. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 2007, 33(4):395-402.
92. Perkins W. Who should have Mohs micrographic surgery?. Curr Opin Otolaryngol Head Neck Surg 2010, 18(4):283-289.
93. Kwon S.Y., Miller S.J. Mohs surgery for melanoma in situ. Dermatol Clin 2011, 29(2):175-183.
94. Thirlwell C., Nathan P. Melanoma-part 2: management. BMJ 2008, 337:a2488.
95. Phan G.Q., Messina J.L., Sondak V.K., et al. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control 2009, 16(3):234-239.
96. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355(13):1307-1317.
97. Wheatley K., Ives N., Hancock B., et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003, 29(4):241-252.
98. Mocellin S., Pasquali S., Rossi C.R., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102(7):493-501.
99. Agarwala S. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way. Am J Clin Dermatol 2003, 4(5):333-346.
100. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
101. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445(7130):851-857.
102. Flaherty K.T. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med 2010, 153(9):587-591.
103. Testori A., Rutkowski P., Marsden J., et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009, 20(Suppl 6):vi22-vi29.
104. Sampson J.H., Carter J.H., Friedman A.H., et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88(1):11-20.
105. Patel J.K., Didolkar M.S., Pickren J.W., et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978, 135(6):807-810.
106. Patnana M., Bronstein Y., Szklaruk J., et al. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 2011, 66(3):224-236.